BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sciascia S, Radin M, Roccatello D, Sanna G, Bertolaccini ML. Recent advances in the management of systemic lupus erythematosus. F1000Res 2018;7:F1000 Faculty Rev-970. [PMID: 30026918 DOI: 10.12688/f1000research.13941.1] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
Number Citing Articles
1 Tocut M, Shoenfeld Y, Zandman-Goddard G. Systemic lupus erythematosus: an expert insight into emerging therapy agents in preclinical and early clinical development. Expert Opin Investig Drugs 2020;29:1151-62. [PMID: 32755494 DOI: 10.1080/13543784.2020.1807004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
2 Uzrail AH, Assaf AM, Abdalla SS. Correlations of Expression Levels of a Panel of Genes (IRF5, STAT4, TNFSF4, MECP2, and TLR7) and Cytokine Levels (IL-2, IL-6, IL-10, IL-12, IFN-γ, and TNF-α) with Systemic Lupus Erythematosus Outcomes in Jordanian Patients. Biomed Res Int 2019;2019:1703842. [PMID: 31871930 DOI: 10.1155/2019/1703842] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
3 Barber MRW, Hanly JG, Su L, Urowitz MB, St Pierre Y, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Petri M, Bruce IN, Dooley MA, Fortin PR, Gladman DD, Sanchez-Guerrero J, Steinsson K, Ramsey-Goldman R, Khamashta MA, Aranow C, Mackay M, Alarcón GS, Manzi S, Nived O, Jönsen A, Zoma AA, van Vollenhoven RF, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Kalunian KC, Inanc M, Kamen DL, Peschken CA, Jacobsen S, Askanase A, Farewell V, Stoll T, Buyon J, Clarke AE. Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care Res (Hoboken) 2020;72:1800-8. [PMID: 31609532 DOI: 10.1002/acr.24092] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Issara-Amphorn J, Somboonna N, Pisitkun P, Hirankarn N, Leelahavanichkul A. Syk inhibitor attenuates inflammation in lupus mice from FcgRIIb deficiency but not in pristane induction: the influence of lupus pathogenesis on the therapeutic effect. Lupus 2020;29:1248-62. [PMID: 32700597 DOI: 10.1177/0961203320941106] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
5 Tang W, Zhou T, Zhong Z, Zhong H. Meta-analysis of associations of vascular endothelial growth factor protein levels and -634G/C polymorphism with systemic lupus erythematosus susceptibility. BMC Med Genet 2019;20:46. [PMID: 30902069 DOI: 10.1186/s12881-019-0783-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
6 Nimesh S, Ahmad MI, Dhama S, Kumar P, Akram M, Hasaroeih NEN. Systemic Lupus Erythematosus Disease: An Overview of the Clinical Approach to Pathogenesis, Diagnosis, and Treatment. Borneo J Pharm 2021;4:91-8. [DOI: 10.33084/bjop.v4i2.1950] [Reference Citation Analysis]
7 Sandoughi M, Salimi S, Shahraki-Ghadimi H, Saravani M. The Impact of TRAIL (C1595T and G1525A) and DR4 (rs20576) Gene Polymorphisms on Systemic Lupus Erythematosus. Biochem Genet 2020;58:649-59. [PMID: 32342239 DOI: 10.1007/s10528-020-09966-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Shandil RK, Dhup S, Narayanan S, Mishra R. Evaluation of the Therapeutic Potential of Mesenchymal Stem Cells (MSCs) in Preclinical Models of Autoimmune Diseases. Stem Cells International 2022;2022:1-8. [DOI: 10.1155/2022/6379161] [Reference Citation Analysis]
9 Plüß M, Tampe B, Niebusch N, Zeisberg M, Müller GA, Korsten P. Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus. Front Med (Lausanne) 2020;7:222. [PMID: 32537456 DOI: 10.3389/fmed.2020.00222] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Radmanesh F, Mahmoudi M, Yazdanpanah E, Keyvani V, Kia N, Nikpoor AR, Zafari P, Esmaeili SA. The immunomodulatory effects of mesenchymal stromal cell-based therapy in human and animal models of systemic lupus erythematosus. IUBMB Life 2020;72:2366-81. [PMID: 33006813 DOI: 10.1002/iub.2387] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
11 Tan MKX, Heng TYJ, Mak A. The Potential Use of Metformin, Dipyridamole, N-Acetylcysteine and Statins as Adjunctive Therapy for Systemic Lupus Erythematosus. Cells 2019;8:E323. [PMID: 30959892 DOI: 10.3390/cells8040323] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
12 Gilcrease GW, Padovan D, Heffler E, Peano C, Massaglia S, Roccatello D, Radin M, Cuadrado MJ, Sciascia S. Is air pollution affecting the disease activity in patients with systemic lupus erythematosus? State of the art and a systematic literature review. Eur J Rheumatol 2020;7:31-4. [PMID: 32023206 DOI: 10.5152/eurjrheum.2019.19141] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]